CMMB vs. MIST, ENTX, ADAG, IVVD, SKYE, VNRX, ORMP, CHRS, IOBT, and SRZN
Should you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include Milestone Pharmaceuticals (MIST), Entera Bio (ENTX), Adagene (ADAG), Invivyd (IVVD), Skye Bioscience (SKYE), VolitionRx (VNRX), Oramed Pharmaceuticals (ORMP), Coherus Oncology (CHRS), IO Biotech (IOBT), and Surrozen (SRZN). These companies are all part of the "pharmaceutical products" industry.
Chemomab Therapeutics vs. Its Competitors
Milestone Pharmaceuticals (NASDAQ:MIST) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.
86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are owned by institutional investors. 19.5% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Chemomab Therapeutics had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 3 mentions for Chemomab Therapeutics and 2 mentions for Milestone Pharmaceuticals. Chemomab Therapeutics' average media sentiment score of 1.12 beat Milestone Pharmaceuticals' score of 0.62 indicating that Chemomab Therapeutics is being referred to more favorably in the news media.
Milestone Pharmaceuticals has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.
Chemomab Therapeutics has lower revenue, but higher earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.
Chemomab Therapeutics' return on equity of -106.70% beat Milestone Pharmaceuticals' return on equity.
Milestone Pharmaceuticals currently has a consensus price target of $7.00, indicating a potential upside of 264.58%. Chemomab Therapeutics has a consensus price target of $8.50, indicating a potential upside of 639.13%. Given Chemomab Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Chemomab Therapeutics is more favorable than Milestone Pharmaceuticals.
Summary
Chemomab Therapeutics beats Milestone Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
Get Chemomab Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CMMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chemomab Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CMMB) was last updated on 7/2/2025 by MarketBeat.com Staff
